OncoDaily Newsletter

Subscribe to our newsletter

Subscribe

Olivia Munn and Mark Kelly Introduce Know Your Risk Act for Breast Cancer

10 Key Trials to Watch at ASH 2026: Multiple Myeloma, Smoldering Myeloma, and AL Amyloidosis

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Thomas Hope: Combining Immunotherapy and PRRT to Improve Outcomes in High-Grade NETs

MAF Test Launches in the US Through NeoGenomics, Challenging Menopause as the Bisphosphonate Gatekeeper

Evis Sala: Addressing Inequalities and Strengthening Cancer Care at European Cancer Summit 2026

St. Jude Researchers Recognized Among the World's Most Highly Cited Scientists in 2026

Natera's Foresight Acquisition Wins 2026 Deal of the Year from the Colorado BioScience Association

Immune Oncology

OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.